Praxis Precision Medicines, Inc. (PRAX) reported a net loss of $303.3 million for the year ended December 31, 2025, compared to a net loss of $182.8 million for the previous year. The increased loss was primarily attributed to a significant rise in research and development expenses, which totaled $267.1 million in 2025, up from $152.4 million in 2024. This surge in R&D spending was partially offset by an increase in other income, net, which rose to $22.9 million from $17.3 million, driven by higher interest income on increased cash and marketable securities balances. The company did not generate any collaboration revenue in 2025, compared to $8.6 million in 2024, due to the completion of its research service obligations under the UCB Biopharma SRL collaboration agreement.
The company's research and development expenses were heavily influenced by its Cerebrum™ platform, which saw an increase of $91.9 million, primarily due to increased spending on the vormatrigine and relutrigine programs. Vormatrigine's ENERGY program and relutrigine's EMBOLD and EMERALD trials contributed significantly to this increase. Personnel-related costs also rose by $15.3 million due to increased headcount, while the Solidus™ platform saw a $5.0 million increase in expenses, driven by the elsunersen program. General and administrative expenses also saw a slight increase of $2.8 million, primarily due to increased professional fees and software costs.
Operationally, Praxis Precision Medicines made significant strides in advancing its clinical-stage programs. The company submitted New Drug Applications (NDAs) to the FDA for both ulixacaltamide for essential tremor and relutrigine for SCN2A-DEE and SCN8A-DEE. The company also initiated commercial preparations and pre-launch activities for both product candidates. The company expects to announce topline results for the EMBRAVE Part A study of elsunersen in the first half of 2026 and topline results for the POWER1 study of vormatrigine in the second quarter of 2026.
Looking ahead, Praxis Precision Medicines anticipates that its current cash, cash equivalents, and marketable securities, combined with proceeds from its January 2026 follow-on public offering, will be sufficient to fund its operating expenditures and capital expenditure requirements into 2028. The company expects to continue to invest heavily in its research and development activities, particularly in advancing its clinical-stage programs and expanding its pipeline. The company also expects to increase its headcount to support its development and commercialization efforts. As of February 16, 2026, the company had 168 employees.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines is a biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly epilepsy and movement disorders. Utilizing genetic insights, its platforms create targeted small molecules and antisense oligonucleotides. The company advances precision medicines through clinical trials, leveraging collaborations and proprietary technologies to address unmet needs in neurological conditions with high patient burden.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.